Precio en el mercado de valores y noticias de Macrogen Inc (038290)

(KRW)	mar 2025	Cambio interanual
Ingresos	40,96 mil M	29,46 %
Gastos operativos	16,98 mil M	24,32 %
Ingresos netos	-2218,91 M	-3,18 %
Margen de beneficio neto	-5,42	20,29 %
Beneficios por acción	—	—
EBITDA	-346,40 M	-122,27 %
Tipo impositivo efectivo	1,39 %	—

Balance general

Activos totales

Responsabilidades totales

(KRW)	mar 2025	Cambio interanual
Efectivo y a corto plazo	43,70 mil M	99,38 %
Activos totales	332,81 mil M	26,75 %
Responsabilidades totales	161,36 mil M	50,90 %
Patrimonio total	171,45 mil M	—
Acciones en circulación	10,84 M	—
Precio-valor contable	1,09	—
Rentabilidad económica	-2,30 %	—
Retorno sobre capital	-3,02 %	—

Flujo de caja

Variación neta del flujo de caja

(KRW)	mar 2025	Cambio interanual
Ingresos netos	-2218,91 M	-3,18 %
Efectivo de operaciones	362,70 M	109,97 %
Efectivo de inversión	-8904,29 M	-43,15 %
Efectivo de financiación	5058,78 M	14,81 %
Variación neta del flujo de caja	-3062,05 M	33,91 %
Flujo de caja libre	-2123,25 M	88,42 %

Información sobre la empresa

Macrogen, Inc. is a South Korean public biotechnology company. The company's headquarters are located in Seoul. The company was founded in 1997 by Jeong-sun Seo, a professor at Seoul National University. It was venture capital-backed until its initial public offering and subsequent listing on the KOSDAQ market in 2000, making it the first Korean biotechnology firm to raise funds through an IPO. The company announced plans in 2010 to map the "Korean genome" based on the notion that United States-backed genome mapping efforts up to that time were representative of the "Caucasian genome" rather than the "Human genome" as claimed. By 2015, the company was described by one news outlet as "a global leader in personalized genomic medicine". Wikipedia

Director ejecutivo

Fundación

5 jun 1997

Sitio web

macrogen.com

Empleados

500